What Is Crotamine? Definition and What Research Reports

Definition

Crotamine is a small, highly basic (cationic) polypeptide originally isolated from the venom of the South American rattlesnake Crotalus durissus terrificus. It belongs to the family of venom myotoxins and has been characterised as a short, disulfide-stabilised polypeptide rich in lysine and arginine residues, a composition that gives it a strong positive charge at physiological pH. In peptide research the word "crotamine" is used in two overlapping senses: as the name of a natural venom toxin studied for its effects on skeletal muscle, and as the name of a cell-penetrating peptide (CPP) scaffold investigated in laboratories as a carrier for molecules that do not normally cross cell membranes. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment, or the use of any substance.

Where crotamine comes from

Crotamine is a natural venom component, not a synthetic analogue of a human hormone. Reviews of the molecule have described it as a small basic polypeptide myotoxin present in the venom of the South American rattlesnake, with its presence varying between individual snakes and populations (PMID 16115660). Because the peptide is short, researchers have also worked with chemically synthesised versions; one paper characterised a synthetic polypeptide crotamine and examined it both as a myotoxin and as a target of combinatorial peptides (PMID 34643765). The existence of a synthetic route is one reason the molecule has stayed in the research literature rather than remaining a purely toxinological curiosity.

What class of molecule it is

Crotamine is classified as a polypeptide toxin. Published descriptions group it with small basic myotoxins, and reviews have emphasised its compact, disulfide-bonded fold and its strong cationic character, features it shares structurally with certain antimicrobial peptides and defensin-like molecules (PMID 21062230). That same cationic surface is what the cell-penetrating literature has focused on: a 2011 review described crotamine as a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties (PMID 22204433).

How the term is used across research contexts

What the published literature reports

Myotoxic activity

The oldest strand of crotamine research concerns its action on skeletal muscle. A 2005 Toxicon review presented a revised view of crotamine as a small basic polypeptide myotoxin from South American rattlesnake venom and summarised the experimental basis for that classification (PMID 16115660). More recently, researchers who produced a synthetic version of the polypeptide characterised it as a myotoxin and screened combinatorial peptides directed against it, an approach framed around identifying binders to the toxin (PMID 34643765). Reviews have noted that the myotoxic identity and the biotechnological interest in crotamine are two faces of the same molecule rather than separate compounds (PMID 22204433).

Cell-penetrating and carrier properties

The second major strand is delivery science. A 2011 review in Current Pharmaceutical Design described crotamine's cell-penetrating properties alongside its myotoxic origin, positioning it within the broader CPP field (PMID 22204433). A 2014 state-of-the-art review in BioMed Research International collected the published work on crotamine as a cell-penetrating peptide from the South American rattlesnake and surveyed how the peptide had been studied in cell models (PMID 24551848). Earlier, a 2010 review in Expert Opinion on Investigational Drugs discussed the biological versatility of this cationic venom peptide and the investigational directions being explored at that time (PMID 21062230).

Immunomodulatory findings

A more recent line of work has examined how the peptide interacts with immune cells: a 2026 paper in Frontiers in Pharmacology addressed the immunomodulatory properties of venom-derived crotamine (PMID 42564012). Taken together with the earlier versatility review (PMID 21062230), this reflects a pattern common to cationic venom peptides, where a single molecule is reported to act at several different biological targets depending on the model system used.

Adverse and toxic findings: What Studies Report

Crotamine is, by definition, a toxin, and the literature treats it that way. The 2005 review described it as a myotoxin from rattlesnake venom, meaning its characterising activity is damage to or dysfunction of skeletal muscle in experimental models (PMID 16115660). The 2022 synthetic-peptide study likewise characterised the molecule as a myotoxin and framed part of its work around finding peptides that bind it (PMID 34643765). The 2011 review made the same dual point, describing crotamine simultaneously as a myotoxin and as a peptide with cell-penetrating properties (PMID 22204433). No human clinical safety dataset appears among the sources summarised here, and the published record described above is preclinical. Specific dose thresholds, exposure durations, and species-by-species toxicity figures are not restated on this page because they fall outside the scope of the titles and abstracts cited.

Regulatory and availability status

No crotamine-based product has been approved as a medicine by the FDA, EMA, or comparable regulators. Where crotamine appears outside academic laboratories, it is typically as a research-use-only reference material for toxinology or peptide-chemistry work, not as a therapeutic. The reviews summarised here consistently frame the molecule as investigational: the 2010 paper appeared in a journal devoted to investigational drugs and discussed crotamine in that framing (PMID 21062230), and the 2014 review positioned the field as a state-of-the-art summary of ongoing laboratory study rather than clinical practice (PMID 24551848).

Common points of confusion

• Crotamine is not crotoxin. Both come from Crotalus durissus terrificus venom, but crotamine is described in the literature as a small basic polypeptide myotoxin (PMID 16115660), a different molecular class from the phospholipase-based venom components.
• "Cell-penetrating peptide" is a mechanism label, not a safety label. The same reviews that described crotamine's cell-penetrating properties also described it as a myotoxin (PMID 22204433).
• Synthetic does not mean non-toxic. The synthetic polypeptide was characterised as a myotoxin in the study that produced it (PMID 34643765).
• Breadth of reported activity is not the same as established use. Reviews have emphasised the peptide's biological versatility across models (PMID 21062230), and newer work has added immunomodulatory findings (PMID 42564012), but neither establishes a clinical role.

Summary of the entry

Crotamine is a short, cationic, disulfide-stabilised polypeptide from South American rattlesnake venom, classified as a myotoxin and separately studied as a cell-penetrating peptide. The published literature that researchers have produced spans toxinology, delivery science, and immunopharmacology, and remains preclinical. Again, this page is educational only and is not medical advice; questions about any peptide belong with a licensed physician.

References

• Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties (Current Pharmaceutical Design, 2011)
• Immunomodulatory properties of venom-derived crotamine (Frontiers in Pharmacology, 2026)
• Biological versatility of crotamine—a cationic peptide from the venom of a South American rattlesnake (Expert Opinion on Investigational Drugs, 2010)
• New view on crotamine, a small basic polypeptide myotoxin from South American rattlesnake venom (Toxicon, 2005)
• State of the art in the studies on crotamine, a cell penetrating peptide from South American rattlesnake (BioMed Research International, 2014)
• Synthetic polypeptide crotamine: characterization as a myotoxin and as a target of combinatorial peptides (Journal of Molecular Medicine, 2022)